In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...
In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...
Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...
ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...
Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...
Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...
India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...
Among these sensors, we further focused on the spatiotemporal dynamics of Rab10 and Rab4 activity during sLTP. We found that postsynaptic stimulation leads to the persistent inactivation of Rab10 and ...
Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the ...
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback